Recap: Esperion Therapeutics Q3 Earnings

Esperion Therapeutics ESPR reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM.

Here's what investors need to know about the announcement.

Esperion Therapeutics beat estimated earnings by 12.9%, reporting an EPS of $-0.81 versus an estimate of $-0.93.

Revenue was up $4.57 million from the same period last year.

Last quarter the company missed on EPS by $0.12 which was followed by a 1.7% drop in the share price the next day.

Here's a look at Esperion Therapeutics's past performance:

Quarter	Q2 2022	Q1 2022	Q4 2021	Q3 2021
EPS Estimate	-0.93	-1.04	-2.27	-2.79
EPS Actual	-1.05	-0.93	-1.77	-2.62
Revenue Estimate	18.71M	15.39M	14.47M	12.85M
Revenue Actual	18.84M	18.84M	15.40M	14.41M

To track all earnings releases for Esperion Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Calendar